Learn About Hereditary Hemorrhagic Telangiectasia

What is the definition of Hereditary Hemorrhagic Telangiectasia?

Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder of the blood vessels that can cause excessive bleeding.

What are the alternative names for Hereditary Hemorrhagic Telangiectasia?

HHT; Osler-Weber-Rendu syndrome; Osler-Weber-Rendu disease; Rendu-Osler-Weber syndrome

What are the causes of Hereditary Hemorrhagic Telangiectasia?

HHT is passed down through families in an autosomal dominant pattern. If a parent has this condition, there is a 50% chance of passing on the gene to a child, regardless of sex of the parent or child. This means the abnormal gene is needed from only one parent in order to inherit the disease.

Scientists have identified four genes involved in this condition. All of these genes appear to be important for blood vessels to develop properly. A variant in any one of these genes can cause a person to have HHT.

What are the symptoms of Hereditary Hemorrhagic Telangiectasia?

People with HHT can develop abnormal blood vessels in several areas of the body. These vessels are called arteriovenous malformations (AVMs).

If they are on the skin, they are called telangiectasias. The most common sites include the lips, tongue, ears, and fingers. The abnormal blood vessels can also develop in the brain, lungs, liver, intestines, or other areas.

Symptoms of this syndrome include:

  • Frequent nosebleeds in children
  • Bleeding in the gastrointestinal tract (GI), including loss of blood in the stool, or dark or black stools
  • Seizures or unexplained, small strokes (from bleeding into the brain)
  • Shortness of breath
  • Enlarged liver
  • Heart failure
  • Anemia caused by low iron
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Hereditary Hemorrhagic Telangiectasia?

Treatments may include:

  • Surgery to treat bleeding in some areas
  • Electrocautery (heating tissue with electricity) or laser surgery to treat frequent or heavy nosebleeds
  • Endovascular embolization (injecting a substance through a thin tube) to treat abnormal blood vessels in the brain and other parts of the body

Some people respond to estrogen therapy, which can reduce bleeding episodes. Iron may also be given if there is a lot of blood loss, leading to anemia. Avoid taking blood-thinning medicines. Some medicines that affect blood vessel development are being studied as possible future treatments.

Some people may need to take antibiotics before having dental work or surgery. People with lung AVMs should avoid scuba diving to prevent decompression sickness (the bends). Ask your provider what other precautions you should take.

Who are the top Hereditary Hemorrhagic Telangiectasia Local Doctors?
Felix A. Ratjen
Elite in Hereditary Hemorrhagic Telangiectasia
Elite in Hereditary Hemorrhagic Telangiectasia
555 University Avenue, M5G 1X8, 
Toronto, ON, CA 

Felix Ratjen practices in Toronto, Canada. Mr. Ratjen is rated as an Elite expert by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. His top areas of expertise are Cystic Fibrosis, Pseudomonas Stutzeri Infections, Hereditary Hemorrhagic Telangiectasia, Telangiectasia, and Lung Transplant.

Keith Mccrae
Elite in Hereditary Hemorrhagic Telangiectasia
Hematology
Elite in Hereditary Hemorrhagic Telangiectasia
Hematology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
Experience:
47+ years
Languages Spoken:
English
Offers Telehealth

Keith Mccrae is a Hematologist in Cleveland, Ohio. Dr. Mccrae has been practicing medicine for over 47 years and is rated as an Elite provider by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. His top areas of expertise are Antiphospholipid Syndrome, Venous Thromboembolism (VTE), Thrombocytopenia, Hereditary Hemorrhagic Telangiectasia, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hereditary Hemorrhagic Telangiectasia
Elite in Hereditary Hemorrhagic Telangiectasia
St. Michael's Hospital, 
Toronto, ON, CA 

Marie Faughnan practices in Toronto, Canada. Ms. Faughnan is rated as an Elite expert by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. Her top areas of expertise are Hereditary Hemorrhagic Telangiectasia, Telangiectasia, Arteriovenous Malformation, Endoscopy, and Liver Embolization.

What are the support groups for Hereditary Hemorrhagic Telangiectasia?

More information and support for people with HHT disorder and their families can be found at:

  • Cure HHT -- curehht.org/
  • National Organization for Rare Disorders -- rarediseases.org/rare-diseases/hereditary-hemorrhagic-telangiectasia/
What is the outlook (prognosis) for Hereditary Hemorrhagic Telangiectasia?

People with this syndrome can live a completely normal lifespan, depending on where in the body the AVMs are located.

What are the possible complications of Hereditary Hemorrhagic Telangiectasia?

These complications can occur:

  • Heart failure
  • High blood pressure in the lungs (pulmonary hypertension)
  • Internal bleeding
  • Shortness of breath
  • Stroke
When should I contact a medical professional for Hereditary Hemorrhagic Telangiectasia?

Contact your provider if you or your child has frequent nose bleeds or other signs of this disease.

How do I prevent Hereditary Hemorrhagic Telangiectasia?

Genetic counseling is recommended for couples who want to have children and who have a family history of HHT. If you have this condition, medical treatments can prevent certain types of strokes and heart failure.

What are the latest Hereditary Hemorrhagic Telangiectasia Clinical Trials?
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN-6400 in Adult Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Summary: The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT

Match to trials
Find the right clinical trials for you in under a minute
Get started
CHORUS: Comprehensive HHT (Hereditary Hemorrhagic Telangiectasia) Outcomes Registry of the United States

Summary: The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowi...

Who are the sources who wrote this article ?

Published Date: April 08, 2025
Published By: Anna C. Edens Hurst, MD, MS, Associate Professor in Medical Genetics, The University of Alabama at Birmingham, Birmingham, AL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Cappell MS, Lebwohl O. Hereditary hemorrhagic telangiectasia. In: Lebwohl MG, Heymann WR, Coulson IH, Murrell DF, eds. Treatment of Skin Disease. 6th ed. Philadelphia, PA: Elsevier; 2022:chap 102.

Centers for Disease Control and Prevention website. Hereditary Hemorrhagic Telangiectasia (HHT). About hereditary hemorrhagic telangiectasia (HHT). www.cdc.gov/hht/about/index.html/. Updated June 18, 2024. Accessed April 16, 2025.

Kwah J, Brandt LJ. Vascular lesions of the gastrointestinal tract. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 11th ed. Philadelphia, PA: Elsevier; 2021:chap 38.

McDonald J, Stevenson DA. Hereditary hemorrhagic telangiectasia. 2000 Jun 26 [updated 2021 Nov 24]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews [Internet]. Seattle, WA: University of Washington. PMID: 20301525 pubmed.ncbi.nlm.nih.gov/20301525/.